Comment on Kanis et al.: "European guidance for the diagnosis and management of osteoporosis in postmenopausal women".
作者信息
Clausen J O
出版信息
Osteoporos Int. 2009 Sep;20(9):1631. doi: 10.1007/s00198-008-0812-y. Epub 2008 Dec 16.
Abstract
摘要
相似文献
1
Comment on Kanis et al.: "European guidance for the diagnosis and management of osteoporosis in postmenopausal women".关于卡尼斯等人的评论：“绝经后女性骨质疏松症诊断和管理的欧洲指南”
Osteoporos Int. 2009 Sep;20(9):1631. doi: 10.1007/s00198-008-0812-y. Epub 2008 Dec 16.
2
Treatment of osteoporosis with parathyroid hormone and teriparatide.甲状旁腺激素和特立帕肽治疗骨质疏松症
Calcif Tissue Int. 2009 Mar;84(3):159-70. doi: 10.1007/s00223-009-9218-x. Epub 2009 Feb 3.
3
Parathyroid hormone as an anabolic skeletal therapy.甲状旁腺激素作为一种骨骼合成代谢疗法。
Drugs. 2005;65(17):2481-98. doi: 10.2165/00003495-200565170-00005.
4
Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.特立帕肽与地诺单抗对完整甲状旁腺激素及骨形成指标的不同影响：AVA骨质疏松症研究
J Clin Endocrinol Metab. 2016 Apr;101(4):1353-63. doi: 10.1210/jc.2015-4181. Epub 2016 Feb 9.
5
Efficacy data on teriparatide (parathyroid hormone) in patients with postmenopausal osteoporosis.特立帕肽（甲状旁腺激素）用于绝经后骨质疏松症患者的疗效数据。
Joint Bone Spine. 2003 Dec;70(6):465-70. doi: 10.1016/j.jbspin.2003.08.002.
6
The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study.首个获批用于治疗骨质疏松症的生物类似药：一项比较药代动力学/药效学研究结果。
Osteoporos Int. 2019 Mar;30(3):675-683. doi: 10.1007/s00198-018-4741-0. Epub 2018 Oct 24.
7
[Treatment of osteoporosis with PTH].甲状旁腺激素治疗骨质疏松症
Clin Calcium. 2014 Jun;24(6):893-902.
8
Comparison of Efficacy of Teriparatide (Parathyroid Hormone 1-34) Alone and in Combination with Zoledronic Acid for Osteoporosis in Postmenopausal Women.特立帕肽（甲状旁腺激素1-34）单独及联合唑来膦酸治疗绝经后女性骨质疏松症的疗效比较
J Coll Physicians Surg Pak. 2021 Feb;31(2):240-242. doi: 10.29271/jcpsp.2021.02.240.
9
Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.阿巴洛肽（一种人甲状旁腺激素相关肽类似物）对绝经后骨质疏松症女性骨矿物质密度的影响。
J Clin Endocrinol Metab. 2015 Feb;100(2):697-706. doi: 10.1210/jc.2014-3718. Epub 2014 Nov 13.
10
The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial.甲状旁腺激素（1-34）与全身振动运动联合治疗绝经后骨质疏松症（PaVOS 研究）：一项随机对照试验。
Osteoporos Int. 2019 Sep;30(9):1827-1836. doi: 10.1007/s00198-019-05029-z. Epub 2019 Jul 15.
引用本文的文献
1
Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety.甲状旁腺功能减退症的 PTH(1-84)治疗：疗效和安全性的前瞻性四年研究。
J Clin Endocrinol Metab. 2013 Jan;98(1):137-44. doi: 10.1210/jc.2012-2984. Epub 2012 Nov 15.
本文引用的文献
1
European guidance for the diagnosis and management of osteoporosis in postmenopausal women.欧洲绝经后女性骨质疏松症诊断与管理指南。
Osteoporos Int. 2008 Apr;19(4):399-428. doi: 10.1007/s00198-008-0560-z. Epub 2008 Feb 12.
2
Fragmentation of parathyroid hormone, a 9.4 kDa polypeptide, in liquid secondary ion mass spectrometry.甲状旁腺激素（一种9.4千道尔顿的多肽）在液体二次离子质谱中的碎片化。
Biol Mass Spectrom. 1993 Jan;22(1):98-100. doi: 10.1002/bms.1200220113.
Zotero 插件